By GREGORY ZELLER

Mark another impressive victory for LineaRX, this time in a two-front battle against cancer.

The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of new therapeutic cancer vaccines.